Skip to main content
HealthReportedLow
2.1

Sanofi launches Phase 1/2 trials of mRNA acne vaccine in adults

Sanofi has begun recruiting adults aged 18-45 for two clinical studies of an experimental mRNA-based acne vaccine, assessing safety, immunogenicity, and efficacy. The candidate targets a common chronic skin condition with no approved vaccine, but early-stage data and timelines remain undisclosed. This is a notable pipeline development for Sanofi's mRNA platform, though far from market approval.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works

Anadolu Agency ENabout 4 hours agoFRengCredibility 51%View source

Score Breakdown

Mosaic Score2.1
Model confidence0.7
Significance0.1
Source credibility0.5
Source

Related signals

8 found